Their first collaboration, Spinraza, a treatment for a deadly rare disease called spinal muscular atrophy, generated $884 million sales last year, its first on the market.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/04/20/biogen-to-pay-ionis-1-billion-to-develop-brain-drugs/
via IFTTT
No comments:
Post a Comment